Currently, the 1st Resistance Point for this stock is $7.13, with a 2nd Resistance Point sitting at $7.18. Meanwhile, this company’s stock has a 1st Support Level at $7.01 and a 2nd Support Level at $6.94. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Viking Therapeutics, Inc. (VKTX) was $7.07. Viking Therapeutics, Inc. (VKTX) stock has lost -$0.12, or -0.70%, in the past five days. In the last full month, these shares have gained $0.35, or 5.21%. In the past three months, this stock’s price has risen by $0.37, or 5.52%. This year-to-date, Viking Therapeutics, Inc. (VKTX) shares have lost -$0.58, or -7.58%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Viking Therapeutics, Inc. (VKTX) stock, Hold % of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”
With 72,264 K shares outstanding, this company currently has a market capitalization of $514,520K. Viking Therapeutics, Inc. (VKTX) generates annual net income of -$22,060 K. This stock has generated a 1-Year Total Return of -36.82%, a 3-Year Total Return of 535.71%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Viking Therapeutics, Inc. (VKTX) reported earnings of -$0.08 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.13 per share, representing a 0.05 difference and 38.46% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.11 represented a -0.02 difference from the consensus estimate calling for -$0.09 per share, which was a -22.22% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.13 per share. This estimate came from a total of 10 Wall Street Analysts. Of those market experts, the high estimate was -$0.09 and the low estimate was -$0.16. In the year-ago quarter, Viking Therapeutics, Inc. (VKTX) generated per-share earnings of -$0.07. If the analysts are correct about the current quarter’s earnings, the growth will be -85.71%.
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 0 insider buys amounting to 0 shares and 0 insider sales amounting to 0 shares. In the past full year, 2 insider purchases were made (involving 103,564 shares) and 2 insider sell-offs equivalent to 6,377 shares.
Moving onto liquidity, Viking Therapeutics, Inc. (VKTX) has a Current Ratio of 66.40, a Quick Ratio of 66.40 and a Cash Ratio of 66.27. Looking even further ahead into the future, its Long-Term Debt to Equity is -46.55.